LABORATORY RESEARCH Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia Scientists reported that PlGF levels are elevated in chronic myeloid leukemia and that PlGF produced by bone marrow stromal cells aggravates disease severity. [Cancer Cell] Angiopoietin-1 Promotes Endothelial Differentiation from Embryonic Stem Cells and Induced Pluripotent Stem Cells Using COMP-angiopoietin-1,researchers explored the effect of angiopoietin-1 on endothelial and hematopoietic differentiation of mouse embryonic stem cells in OP9 co-culture system. [Blood] Plasmodium Falciparum Uses a Key Functional Site in Complement Receptor Type-1 for Invasion of Human Erythrocytes Using recombinant complement receptor-type 1 (CR1) constructs investigators mapped the recognition site for PfRh4 to complement control protein modules 1 to 3 at the membrane-distal amino terminus of CR1. [Blood] Regulation of the Activation of the Fanconi Anemia Pathway by the p21 Cyclin-Dependent Kinase Inhibitor In this study, scientists have examined the roles of the p53 tumor suppressor protein, as well as its downstream target, the p21Cip1/Waf1 cyclin-dependent kinase inhibitor, in the regulation of the activation of the fanconi anemia-BRCA pathway. [Oncogene] LPS Hypersensitivity of gp130 Mutant Mice Is Independent of Elevated Hemopoietic TLR4 Signaling Researchers reported here that in lipopolysaccharide (LPS)-treated macrophages from gp130F/F mice, gp130 hyperactivation upregulated the LPS-induced expression of inflammatory mediators downstream of Janus kinase/STAT, nuclear factor κ-light-chain-enhancer of activated B cells, interferon regulatory factor and c-Jun N-terminal kinase/p38 mitogen-activated protein kinase pathways. [Immunol Cell Biol] c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells Investigators presented data showing that the oncoprotein c-MYC is a direct transcriptional regulator of a large set of ATP-binding cassette transporters in chronic myeloid leukemia. [Mol Cancer Res] CLINICAL RESEARCH Combination of Pegylated Interferon-α2b with Imatinib Increases Molecular Response Rates in Patients with Low or Intermediate Risk Chronic Myeloid Leukemia Scientists randomized newly diagnosed chronic phase chronic myeloid leukemia patients with a low or intermediate Sokal risk score and in imatinib induced complete hematological remission either to receive a combination of pegylated IFN-α2b 50 µg weekly and imatinib 400 mg daily (n=56) or to receive imatinib 400mg daily monotherapy (n=56). [Blood] Trends in Allogeneic Stem Cell Transplantation for Multiple Myeloma: A Center for International Blood and Marrow Transplant Research Analysis Researchers analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-94 (n=343), 1995-2000 (n=376), and 2001-05 (n=488). [Blood] Pomalidomide Plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory Disease Investigators opened two sequential phase II trials using the Pom/dex regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. [Blood] Comparison of High-Dose Cytarabine and Timed-Sequential Chemotherapy As Consolidation for Younger Adults with AML in First Remission: The ALFA-9802 Study To assess the value of administering timed-sequential chemotherapy (two therapeutic sequences separated by a four-day interval-free chemotherapy) or high-dose cytarabine cycles in consolidation therapy for acute myeloid leukemia (AML), 459 patients aged 15 to 50 years were enrolled in the prospective randomized Acute Leukemia French Association (ALFA)-9802 trial. [Blood] |